Drugs / Roseomonas mucosa
Roseomonas mucosa
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03018275 | Apr 2017 → Oct 2019 | atopic eczema | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06096857 Comparator | Oct 2024 → Jan 2027 expected | atopic eczema | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Roseomonas mucosa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06096857 ↗ |
| Known as | R mucosa | “introducing bacteria, R mucosa, from healthy skin onto the skin of someone with AD helps treat the disease.” NCT03018275 ↗ |
| Known as | RSM2015 | “Roseomonas mucosa (RSM2015) and Cardamom seeds” NCT06096857 ↗ |
| Modality | Other / unclassified | “a topical formulation of a live biotherapeutic containing Roseomonas mucosa” NCT06096857 ↗ |
| Route | Topical | “Part 1 participants will spray R mucosa on their arm twice per week for 6 weeks.” NCT03018275 ↗ |